SABCS 2024 | Updates in liquid biopsy and biomarker development at SABCS 2024

Jenna Canzoniero • 13 Dec 2024

SABCS 2024

Breast Cancer

Jenna Canzoniero, MD, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, comments on recent developments in liquid biopsy and biomarker development in breast cancer, with a focus on minimal residual disease (MRD) testing and its potential to guide therapy escalation or de-escalation. Topics include emerging technologies for detecting structural variants in MRD and the development of predictive biomarkers for CDK4/6 inhibitors. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.